文章预览
Regeneron's hopes to beat Bristol Myers Squibb in Lag3 have taken a twist, with the company blaming a "clerical error" for declining results in melanoma patients receiving its contender fianlimab, plus Libtayo, following perioperative PD-(L)1 therapy. It was these patients who last year helped fianlimab's case, but this year’s ESMO meeting showed much less impressive results. Regeneron is well behind, with pivotal data in first-line melanoma due next year and results with a fixed-dose combination not expected until 2027. The group will need something special to overtake Bristol, which has had its Lag3/PD-1 combo, Opdualag, approved in melanoma since 2022. Perioperative waning Regeneron's data came from a phase 1 trial of fianlimab, with or without Libtayo, in solid tumours. Zooming in on melanoma, the study had already impressed in PD-(L)1-naive patients, and results presented at ASCO 2023 also suggested a benefit in those who had previously received perioperative checkpoint inhibit
………………………………
